Super Bowl Ads Hijacked

Close-up of an official NFL football with team logos and leather texture

Big Pharma and telehealth didn’t just buy Super Bowl airtime this year—they bought a national megaphone to redefine “health” as a subscription, a shot, and a screening.

Story Snapshot

Super Bowl LX featured an unusually large cluster of health-related ads pushing GLP-1 weight-loss drugs, blood-test screenings, and anti–ultra-processed food messaging.
Novo Nordisk promoted Wegovy with celebrity talent while telehealth firms Ro and Hims & Hers pitched broader “longevity” services and access models.
Novartis and Boehringer Ingelheim used football humor and action-movie styling to encourage PSA and kidney-risk blood/urine testing.
Medical experts praised some awareness-raising goals but warned ads can underplay side effects, long-term commitments, and lifestyle fundamentals.

Super Bowl LX becomes a health-care sales floor

Super Bowl LX delivered a clear signal: health and longevity are now mainstream advertising categories, not niche public-service messages. Multiple brands bought premium slots to promote GLP-1 weight-loss drugs, telehealth “longevity” programs, and lab-style screening tests, aiming at a unified audience reported around 120 million. Analysts described the surge in pharma and health ads as a turning point, especially compared with earlier years when such spots were less frequent and more purely educational.

Telehealth companies used celebrity credibility to frame medical weight loss and “prevention” as convenient and normal. Ro’s campaign with Serena Williams positioned GLP-1 access alongside heart-health and weight messaging, while Hims & Hers leaned into the provocative claim that “rich people live longer,” narrated by Common, to sell a bundle of services that can include GLP-1s, diagnostics, and other longevity products. The pitch was less about a single drug and more about ongoing membership-style care.

GLP-1 hype meets real-world constraints: side effects, muscle loss, and long-term use

Medical commentary after the game highlighted the gap between ad-friendly promises and patient realities. Physicians noted GLP-1 therapy often requires long-term use and can carry side effects that don’t fit neatly into a 30-second narrative. Another recurring concern was lean muscle loss and the need for lifestyle support—protein intake, resistance training, and sustained behavior change—so weight loss doesn’t come at a functional cost. Even supporters cautioned that insurance coverage and affordability remain unresolved for many families.

Novo Nordisk’s Wegovy spot, featuring DJ Khaled and Kenan Thompson, pushed brand recognition at a moment when the drug’s pill form had just gained FDA approval in January 2026. That regulatory milestone matters, but it doesn’t automatically settle the kitchen-table questions viewers care about: what does it cost, what does insurance cover, and what tradeoffs come with long-term dependence on a medication? The ads raised awareness, yet they also reinforced how commercial incentives can outpace clear consumer understanding.

Blood-test screening ads push prevention, but simplicity can mislead

Not all of the night’s health messaging centered on weight loss. Novartis ran “Relax Your Tight End,” using NFL tight ends and coach Bruce Arians to nudge men toward PSA blood testing for prostate cancer, a disease risk often summarized as affecting 1 in 8 men. Boehringer Ingelheim’s “Mission:Detect the SOS” spotlighted kidney and diabetes risk via uACR testing. Both campaigns tried to normalize screening as routine and responsible, rather than scary or stigmatized.

“Eat real food” messaging resonates—yet experts dispute the tone

The MAHA Center’s ad featuring Mike Tyson and his son Amir took the opposite approach from pharma: it targeted ultra-processed foods with blunt language and directed viewers to RealFood.gov. Some medical voices said the ad could help Americans connect chronic disease risk to dietary patterns, which is a legitimate concern in a country struggling with obesity and metabolic illness. Other critics argued the messaging risked fat-shaming or ignored broader social determinants that shape diet and health choices.

What conservative families should watch: choice, transparency, and medical overreach

For voters frustrated by years of top-down “expert” culture, the Super Bowl’s health blitz landed as a paradox. The ads promoted personal responsibility—screen early, manage weight, eat better—while also nudging Americans toward permanent medical dependency and subscription care models. The strongest takeaway isn’t that prevention is bad; it’s that consumers need clear, non-spun information to make choices without being herded by marketing budgets. The research available does not yet show measurable behavior outcomes from these ads.

Super Bowl advertising has always been about power, money, and culture—and in 2026, health joined that list in a big way. Whether viewers see a welcome push toward early detection or a glossy campaign to medicalize everyday life depends on what comes next: transparent pricing, honest risk communication, and a renewed focus on basics that don’t require a prescription. Until those pieces are clearer, the safest posture is informed skepticism paired with common-sense prevention.